X2S Stock Overview Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteSinopharm Group Co. Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sinopharm Group Historical stock prices Current Share Price HK$2.66 52 Week High HK$2.72 52 Week Low HK$1.84 Beta 0.85 1 Month Change 6.39% 3 Month Change 15.49% 1 Year Change 13.04% 3 Year Change 40.11% 5 Year Change -16.81% Change since IPO 51.25%
Recent News & Updates
New minor risk - Financial position Nov 13
Third quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.64 in 3Q 2023) Oct 28
Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024 Oct 14
Investor sentiment improves as stock rises 16% Oct 02
New minor risk - Financial position Sep 25
Second quarter 2024 earnings released Sep 25 See more updates
New minor risk - Financial position Nov 13
Third quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.64 in 3Q 2023) Oct 28
Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024 Oct 14
Investor sentiment improves as stock rises 16% Oct 02
New minor risk - Financial position Sep 25
Second quarter 2024 earnings released Sep 25 Sinopharm Group Co. Ltd. Announces Change in President Aug 28
Sinopharm Group Co. Ltd. Announces Management Changes Aug 27
Second quarter 2024 earnings released Aug 25
Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Aug 09
Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024 Jun 14
Upcoming dividend of CN¥0.87 per share Jun 10
Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.74 in FY 2022) Apr 28
Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Apr 17
Dividend of CN¥0.87 announced Mar 27
Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.73 in FY 2022) Mar 25
Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024 Mar 13
Investor sentiment improves as stock rises 16% Jan 29
Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022) Oct 31
Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023 Oct 14
Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor Sep 16
Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.72 in 2Q 2022) Aug 28
Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Aug 16
Investor sentiment deteriorates as stock falls 17% Aug 08 Sinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023
Upcoming dividend of CN¥0.82 per share at 3.4% yield Jun 12
Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director May 19
Full year 2022 earnings released: EPS: CN¥2.73 (vs CN¥2.49 in FY 2021) Mar 29
Sinopharm Group Co. Ltd. Approves Board Appointments Dec 24
Third quarter 2022 earnings released Oct 28
Sinopharm Group Co. Ltd. to Report Q3, 2022 Results on Oct 26, 2022 Oct 11
Second quarter 2022 earnings released Aug 30
Sinopharm Group Co. Ltd. to Report First Half, 2022 Results on Aug 26, 2022 Aug 13
Sinopharm Group Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable No Later Than 23 August 2022 Jun 24
Upcoming dividend of CN¥0.75 per share Jun 20
Sinopharm Group Co. Ltd. Announces Executive Changes Jun 18
Sinopharm Group Co. Ltd. Announces Resignation of Deng Jindong as Member of Audit Committee and Remuneration Committee of Board Jun 11
Sinopharm Group Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 23 August 2022 Jun 03
Full year 2021 earnings released: EPS: CN¥2.49 (vs CN¥2.31 in FY 2020) Apr 28
Sinopharm Group Co. Ltd. to Report Q1, 2022 Results on Apr 21, 2022 Apr 12
Sinopharm Group Co. Ltd., Annual General Meeting, Jun 23, 2022 Mar 23
Third quarter 2021 earnings released: EPS CN¥0.68 (vs CN¥0.75 in 3Q 2020) Oct 27
Independent Chief Supervisor Yifang Wu has left the company Jun 14
Boyu, Sinopharm Reportedly Among Bidders Shortlisted for Mundipharma China Jun 09
Upcoming dividend of CN¥0.69 per share Jun 08
Joint Company Secretary has left the company Apr 29
Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.11 in FY 2019) Apr 25
Full year 2020 earnings released Mar 23
Sinopharm Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021 Mar 10 Sinopharm Group Co. Ltd. Announces Chief Financial Officer Changes
Sinopharm Group Co., Ltd. Announces Board Appointments Jan 17
Sinopharm Group Co., Ltd. Announces Board Changes Jan 13
New 90-day high: €2.20 Nov 26
Third quarter earnings released Oct 24
New 90-day low: €1.81 Oct 15
Sinopharm Group Co., Ltd. to Report Nine Months, 2020 Results on Oct 22, 2020 Oct 13
New 90-day low: €1.84 Sep 25
Sinopharm Group Co., Ltd. Appoints Management Team Sep 20 Sinopharm Group Co., Ltd. Appoints Directors
First half earnings released Sep 19
New 90-day low - €1.95 Sep 05
Earnings released Aug 25
Sinopharm Group Co., Ltd. to Report Q2, 2020 Results on Aug 21, 2020 Aug 10 Shareholder Returns X2S DE Healthcare DE Market 7D 0.8% -0.2% -0.3% 1Y 13.0% 16.5% 7.0%
See full shareholder returns
Return vs Market: X2S exceeded the German Market which returned 6.8% over the past year.
Price Volatility Is X2S's price volatile compared to industry and market? X2S volatility X2S Average Weekly Movement 6.1% Healthcare Industry Average Movement 4.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: X2S has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: X2S's weekly volatility (6%) has been stable over the past year.
About the Company Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Show more Sinopharm Group Co. Ltd. Fundamentals Summary How do Sinopharm Group's earnings and revenue compare to its market cap? X2S fundamental statistics Market cap €8.47b Earnings (TTM ) €1.14b Revenue (TTM ) €77.72b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) X2S income statement (TTM ) Revenue CN¥590.35b Cost of Revenue CN¥543.16b Gross Profit CN¥47.18b Other Expenses CN¥38.53b Earnings CN¥8.65b
Dividends
4.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 01:05 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sinopharm Group Co. Ltd. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Mann Barclays Derrick Sun BNP Paribas Securities (Asia) Bo Li BofA Global Research
Show 40 more analysts